Curbing High Risk of Non-obstructive smokers

niversity Hospital of Basel0 个研究点目标入组 158 人开始时间: 2022年8月18日最近更新: 2022年8月29日

适应症

试验速览

暂无简介。

•Both groups:
•1. Able to give informed consent as documented by signature
•2. Age =40 years
•3. FEV1/FVC =0.70
•Intervention group: Current or past smokers
•4. =10 pack years
•5. At least one symptom from the following: (Cough, Phlegm, Shortness of breath)
•Control group: Minimal smoking exposure
•6. =1 pack year tobacco-smoking history

•Both groups:
•1. Pregnant or lactating women
•2. Current increased (more than usual) respiratory symptoms
•3. Concomitant respiratory disease (eg asthma, ILD) or clinically significant bronchiectasis
•4. Unstable cardiovascular disease
•5. Inability to follow the procedures of the study, e.g. due to language problems, dementia, etc.
•6. Active pulmonary infection or prior pulmonary infection where antibiotic and/or steroid treatment was completed =4 weeks prior to enrolment
•7. Enrolment in an interventional clinical trial within last 30 days
•8. Severe immunosuppression including manifested AIDS, organ transplantation, ongoing chemotherapy for cancer or neutropenia (<500*10^9/L)
•9. Chronic use of oral steroids (>10 mg per day)
•Intervention group:
•10. Severe allergy to milk proteins
•11. Known allergy or intolerance to the study medication

发起方

niversity Hospital of Basel